Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.

Cook, Gordon; Ashcroft, John; Fernandez, Mariana; Henshaw, Sarah; Khalaf, Zeyad; Pratt, Guy; Tailor, Anish; Rabin, Neil

Cook, Gordon; Ashcroft, John; Fernandez, Mariana; Henshaw, Sarah; Khalaf, Zeyad; Pratt, Guy; Tailor, Anish; Rabin, Neil.

Afiliación

Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Ashcroft J; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
Fernandez M; Department of Haematology, Pinderfields General Hospital, Wakefield, United Kingdom.
Henshaw S; Janssen Europe, the Middle East and Africa (EMEA), Beerse, Belgium.
Khalaf Z; Department of Haematology, Nottingham University Hospitals, Nottingham, United Kingdom.
Pratt G; Janssen Europe, the Middle East and Africa (EMEA), Beerse, Belgium.
Tailor A; Department of Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.
Rabin N; Department of Haematology, University College London Hospitals, London, United Kingdom.

Front Oncol ; 13: 1063144, 2023.

Article en En | MEDLINE | ID: mdl-36910662

Palabras clave

daratumumab; intravenous; multiple myeloma; quality of life; subcutaneous

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google